Center for Breakthrough Medicines Plans for an Even Larger Dive into Cell Therapy Manufacturing

As the pipeline for cell ther­a­pies grows, man­u­fac­tur­ers and CD­MOs are look­ing to get in on the ac­tion.

The Cen­ter for Break­through Med­i­cines, a Penn­syl­va­nia-based CD­MO, is part­ner­ing with Dis­cov­ery Labs to ac­cel­er­ate plans to build the ca­pac­i­ty to man­u­fac­ture more than 10,000 pa­tient ther­a­pies at their head­quar­ters in King of Prus­sia, PA, a sub­urb of Philadel­phia.

The plan­ning has be­gun on the man­u­fac­tur­ing suites and sup­port­ing in­fra­struc­ture, and when com­plet­ed the fa­cil­i­ty, ac­cord­ing to CBM’s con­ser­v­a­tive cal­cu­la­tions, the site will be able to pro­duce around 10,000 batch­es of prod­uct per year in the space.

Read the full article at: endpts.com

Related Articles

CoJourney to Open CDMO for Cell and Gene Therapies at Spring House Innovation Park in Montgomery County

CoJourney to Open CDMO for Cell and Gene Therapies at Spring House Innovation Park in Montgomery County

FDA Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for subgroup of Patients with Critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir

FDA Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for subgroup of Patients with Critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir

Passage Bio Doses First Patient in Global Clinical Trial for Infantile Krabbe Disease, A Rare Fatal Pediatric Condition

Passage Bio Doses First Patient in Global Clinical Trial for Infantile Krabbe Disease, A Rare Fatal Pediatric Condition